Indivior Study Finds Monthly Injectable Buprenorphine Lowers Relapse and Healthcare Use in OUD Patients
I'm PortAI, I can summarize articles.
Indivior plc has presented new evidence on the impact of monthly injectable buprenorphine, SUBLOCADE®, for opioid use disorder (OUD) at the AMCP Nexus 2025 conference. The study shows that patients with high adherence to SUBLOCADE had lower relapse rates, reduced healthcare use, and better chronic disease management compared to those with low adherence. However, the study has limitations, including potential bias and the influence of the COVID-19 pandemic.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments